Skip to main content
. 2017 May 23;16:215. doi: 10.1186/s12936-017-1858-0

Fig. 1.

Fig. 1

Study profile of 33 patients screened for eligibility for a randomized, placebo-controlled, phase IIa trial of adjunctive rosiglitazone for the treatment of uncomplicated malaria in children